Advanced glycation end products and the progressive course of renal disease

American Journal of Kidney Diseases

Volumn 38, Issue 4 SUPPL. 1, 2001, Pages

  Heidland, A ^a   Sebekova, K ^a   Schinzel, R ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Advanced glycation end products (AGEs); Carboxymethyl lysine (CML); Diabeticnephropathy (DN); Oxidative stress; Renal function

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMINOGUANIDINE; CATHEPSIN; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LYSINE; MALONALDEHYDE; PENTOSIDINE; PYRIDOXAMINE; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

CELL PROLIFERATION; CONFERENCE PAPER; CROSS LINKING; CYCLIZATION; DIABETIC NEPHROPATHY; DISEASE COURSE; EXTRACELLULAR MATRIX; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; MESANGIUM CELL; OXIDATIVE STRESS; PROTEIN EXPRESSION;

EID: 0034817423     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2001.27414     Document Type: Conference Paper

References (43)

1. Lilly lecture 1993. Glycation and diabetic complications
2. Glycation cross-links inhibit matrix metalloproteinase-2 activation in vascular smooth muscle cells cultured on collagen lattice
3. Lipid and lipoprotein modification by AGEs: Role in atherosclerosis
4. AGEs and their interaction with AGE-receptors in vascular disease and diabetes. I. The AGE concept
5. Cell activation by glycated proteins, AGE receptors, receptor recognition factors and functional classification of AGE
6. Advanced glycation end products in diabetic nephropathy
7. Advanced glycation end-products: A review
8. RAGE: A new target for the prevention and treatment of the vascular and inflammatory complications of diabetes
9. Orally absorbed reactive glycation products (glycotoxins): An environmental risk factor in diabetic nephropathy
10. 1c as markers of diabetic complications
11. Alteration in non-enzymatic biochemistry in uraemia: Origin and significance of "carbonyl stress" in long term uraemic complications
12. Enhanced AGE levels in patients with liver cirrhosis
13. Renal fate of circulating advanced glycated end products (AGE): Evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells
14. Reactive glycosylation end products in diabetic uremia and treatment of renal failure
15. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications
16. Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes
17. Immunocytochemical detection of advanced glycation end products in rat renal tissue as a function of age and diabetes
18. Advanced glycated end products in diabetic tissues using monoclonal antibody to pyrraline
19. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease
20. Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of protein in diabetic glomerular lesions
21. Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients
22. Expression of receptors for advanced glycosylated end-products in renal disease
23. Plasma levels of pentosidine in diabetic patients: An advanced glycation end product
24. Increased accumulation of the glyoxidation product N (epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging
25. E-(carboxymethyl)lysine levels in type 2 diabetic patients - Role of renal function
26. Importance of oxidatively modified proteins in chronic renal failure
27. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats
28. Upregulation of mesangial growth factor and extracellular matrix synthesis by advanced glycation end products via a receptor-mediated mechanism
29. PDGF and TGF-beta mediate collagen production by mesangial cells exposed to advanced glycosylation end products
30. II in neonatal mesangial cells
31. 1
32. 1
33. 1
34. Differences in the modulating potential of advanced glycation end product (AGE) peptides versus AGE proteins
35. Nonenzymatically glycated albumin (Amadori adducts) enhances nitric oxide synthase activity and gene expression in endothelial cells
36. Early glycosylation products induce glomerular hyperfiltration in normal rats
37. Role of Amadori modified non-enzymatically glycated serum proteins in the pathogenesis of diabetic nephropathy
38. Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation
39. Amadorins: Novel post-Amadori inhibitors of advanced glycation end products
40. N-Phenacylthiazolium bromide (PTB) decreases renal AGE levels and increases urinary AGE excretion, without ameliorating diabetic nephropathy in C57BL/6 mice
41. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation end-products
42. Nitric oxide inhibits the formation of advanced glycation end products
43. Advanced glycation end-product concentrations in sub-totally nephrectomised rats: Beneficial effects of angiotensin II receptor I antagonist losartan